hospital3.jpg (copy)

Russell C. Cattley, VMD, PhD, DACVP

Dr. Russell Cattley, Tyler & Frances Young Professor of Pathology, earned the VMD degree in 1980 from the University of Pennsylvania.  He completed a residency in veterinary and comparative pathology, jointly conducted by Auburn University and the University of Alabama-Birmingham (1980-83), and board certification (ACVP) in anatomic veterinary pathology in 1984.  He received the PhD degree in 1988 from the University of North Carolina-Chapel Hill, where he completed his dissertation in experimental hepatocarcinogenesis under the direction of Dr. James Popp.  He was appointed Assistant Professor of Pathology at the College of Veterinary Medicine at N.C. State University in 1988.  In 1990, he joined the scientific staff of the Chemical Industry Institute of Toxicology in Research Triangle Park, NC.  In 1999, Dr. Cattley left CIIT to work at the biotechnology company Amgen, in Thousand Oaks, CA, where he became Executive Director of Pathology with responsibility for building and leading a multi-site group of pathologists and laboratory staff supporting Amgen’s research and development activities.  Dr. Cattley joined the faculty at College of Veterinary Medicine in 2011 where he actively participates in the teaching and research missions of the college and serves in the anatomic pathology services of the Pathobiology Department.

334-844-2693 
rcc0022@auburn.edu

Research Interests

Dr. Cattley’s research interests include 1) experimental and toxicologic pathology; 2) mechanisms of carcinogenesis and anti-cancer therapies; and 3) pathogenesis of liver disease.

Selected Publications

  • Coxon A., Bready J., Min H., Kaufman S., Leal J., Yu D., Lee T.A., Sun J.R., Estrada J., Bolon B., McCabe J., Wang L., Rex K., Caenepeel S., Hughes P., Cordover D., Kim H., Han S.J, Michaels M.L., Hsu E., Shimamoto G., Cattley R., Hurh E., Nguyen L., Wang S.X., Ndifor A., Hayward I.J., Falcón B.L., McDonald D.M., Li L., Boone T., Kendall R., Radinsky R, and Oliner J.D.  “Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.”  Mol Cancer Ther.  9:2641-2651 (2010).
  • Henley C., Davis J., Miller G., Shatzen E., Cattley R., Li X., Martin D., Yao W., Lane N., and Shalhoub V.  “The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.”  Eur J Pharmacol. 616:306-313, 2009.
  • Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., Chen C., Li L., Cattley R.C., Van G., Scully S., Elliott R., Grisanti M., Morony S., Tan H.L., Asuncion F., Li X., Ominsky M.S., Stolina M., Dwyer D., Dougall W.C., Hawkins N., Boyle W.J., Simonet W.S., and Sullivan J.K. “Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.” J Bone Miner Res. 24(2):182-95, 2009.
  • Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., Stolina M, Kostenuik P.J, Demer L.L. “Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.” Circulation 117(3):411-20, 2008.
  • Lee S.S., Naqvi T.Z., Forrester J., Cattley R., Shah A., Frantzen M., Miyamoto T., Kaufman S., Price M.J.., Lill M., and Makkar R.R.   “The effect of granulocyte colony stimulating factor on regional and global myocardial function in the porcine infarct model.”  International Journal of Cardiology. 116:225-30, 2007.
  • Polverino A., Coxon A., Starnes C., Diaz Z ., Demelfi T., Wang L., Bready J., Estrada J., Cattley R., Kaufman S., Chen D., Gan Y., Kumar G., Meyer J., Neervannan S., Alva G., Talvenheimo J., Montestruque S., Tasker A., Patel V., Radinsky R., and Kendall R.  “AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts,” Cancer Research. 66:8715-21, 2006.
  • Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., Morony S., Adamu S., Geng Z., Qiu W., Kostenuik P., Lacey D.L., Simonet W.S., Bolon B., Qian X., Shalhoub V., Ominsky M.S., Zhu Ke H., Li X., and Richards W.G. “Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia,”  Bone 39:754-66, 2006.
  • Burgess T., Coxon A.. Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Sun J., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R., and Kendall R.  “Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors,” Cancer Research 66:1721-17299, 2006.
  • Henley C., Colloton M., Cattley R.C., Shatzen E., Towler D.A., Lacey D., and Martin D. “1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism,” Nephrology Dialysis Transplantation 20:1370-1277, 2005.
  • Cattley, R.C. and Radinsky, R.R. “Cancer therapeutics: understanding the mechanism of action,” Toxicologic Pathology 32 Suppl 1:116-21, 2004.
  • Howroyd P., Swanson C., Dunn C., Cattley R.C., and Corton JC. “Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha),” Toxicologic Pathology 32:591-9, 2004.
  • Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S.J., Hawkins, N., Rosenfeld, R., Davy, E., Graham, K., Jacobsen, F., Stevenson, S., Ho, J., Chen, Q., Hartmann, T., Michaels, M., Kelley, M., Li, L., Sitney, K., Martin, F., Sun, JR., Zhang, N., Lu, J., Estrada J., Kumar, R., Coxon, A., Kaufman, S., Pretorius, J., Scully, S., Cattley, R., Payton, M., Coats, S., Nguyen, L., Desilva, B., Ndifor, A., Hayward, I., Radinsky, R., Boone, T., and Kendall, R.  “Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2,” Cancer Cell 6:507-16, 2004.
  • Cattley, R.C. “Peroxisome proliferators and receptor-mediated hepatic carcinogenesis,” Toxicologic Pathology. 32 Suppl 2:6-11, 2004. 
Auburn University | College of Veterinary Medicine | Auburn, Alabama 36849 | (334) 844-4546
Webmaster | Website Feedback | Privacy | Copyright ©